Summary

The approved dose of rituximab for the treatment of rheumatoid arthritis (RA) is 1000 mg × 2, but some data have suggested similar clinical efficacy with rituximab 500 mg × 2. The objective of this analysis was to compare the efficacy of the 2 doses, given as first or second treatment courses. The data for this analysis were obtained from the European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid Arthritis [CERERRA], which includes 10 European registries.